Clearside Begin Period Cash Flow vs Ev To Free Cash Flow Analysis

CLSD Stock

USD 0.99 0.01 1.00%

Clearside Biomedical financial indicator trend analysis is way more than just evaluating Clearside Biomedical prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Clearside Biomedical is a good investment. Please check the relationship between Clearside Biomedical Begin Period Cash Flow and its Ev To Free Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearside Biomedical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For information on how to trade Clearside Stock refer to our How to Trade Clearside Stock guide.

Begin Period Cash Flow vs Ev To Free Cash Flow

Begin Period Cash Flow vs Ev To Free Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Clearside Biomedical Begin Period Cash Flow account and Ev To Free Cash Flow. At this time, the significance of the direction appears to have no relationship.

The correlation between Clearside Biomedical's Begin Period Cash Flow and Ev To Free Cash Flow is 0.06. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Ev To Free Cash Flow in the same time period over historical financial statements of Clearside Biomedical, assuming nothing else is changed. The correlation between historical values of Clearside Biomedical's Begin Period Cash Flow and Ev To Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Clearside Biomedical are associated (or correlated) with its Ev To Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ev To Free Cash Flow has no effect on the direction of Begin Period Cash Flow i.e., Clearside Biomedical's Begin Period Cash Flow and Ev To Free Cash Flow go up and down completely randomly.

Correlation Coefficient

0.06

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Ev To Free Cash Flow

A valuation metric comparing the company's enterprise value to its free cash flow, used to evaluate whether a company is undervalued or overvalued.

Most indicators from Clearside Biomedical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Clearside Biomedical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearside Biomedical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For information on how to trade Clearside Stock refer to our How to Trade Clearside Stock guide.The current year's Selling General Administrative is expected to grow to about 12.1 M, whereas Issuance Of Capital Stock is forecasted to decline to about 1.6 M.

Clearside Biomedical fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Other Liab	Net Tangible Assets	Other Assets	Long Term Debt
Total Assets		0.29	0.39	0.51	0.77	0.28	-0.42	-0.48	0.51	0.76	0.28	0.03	0.99	0.53	0.39	0.01	0.35	0.48	0.1	0.31	1.0	0.56	0.34	0.9	-0.47	0.54
Short Long Term Debt Total	0.29		0.38	0.3	-0.17	0.9	0.57	-0.55	0.29	0.28	0.79	-0.17	0.27	0.6	0.36	0.6	0.19	0.35	0.45	0.86	0.26	0.37	0.64	0.24	-0.44	0.28
Other Current Liab	0.39	0.38		0.73	0.08	0.57	-0.03	-0.71	0.54	0.45	0.52	-0.07	0.33	0.63	0.68	0.24	0.48	0.73	0.4	0.59	0.36	0.65	0.55	0.28	-0.36	0.02
Total Current Liabilities	0.51	0.3	0.73		0.35	0.39	0.0	-0.63	0.76	0.32	0.3	-0.18	0.49	0.55	0.46	-0.09	0.34	0.66	0.1	0.32	0.5	0.57	0.17	0.5	-0.35	0.3
Total Stockholder Equity	0.77	-0.17	0.08	0.35		-0.17	-0.49	-0.21	0.38	0.41	-0.21	-0.13	0.76	0.26	0.21	-0.61	0.29	0.33	-0.5	-0.13	0.79	0.39	-0.01	0.91	-0.13	0.45
Property Plant And Equipment Net	0.28	0.9	0.57	0.39	-0.17		0.34	-0.79	0.2	0.46	0.92	-0.1	0.24	0.82	0.66	0.55	0.47	0.63	0.44	0.99	0.25	0.64	0.84	0.24	-0.59	0.07
Net Debt	-0.42	0.57	-0.03	0.0	-0.49	0.34		0.09	0.23	-0.62	0.15	-0.44	-0.4	-0.11	-0.26	0.22	-0.42	-0.22	0.06	0.25	-0.43	-0.31	-0.06	-0.3	0.26	0.22
Retained Earnings	-0.48	-0.55	-0.71	-0.63	-0.21	-0.79	0.09		-0.32	-0.67	-0.76	0.0	-0.41	-0.98	-0.93	-0.16	-0.79	-0.96	-0.21	-0.82	-0.45	-0.95	-0.81	-0.49	0.8	-0.07
Accounts Payable	0.51	0.29	0.54	0.76	0.38	0.2	0.23	-0.32		0.02	0.12	-0.17	0.52	0.24	0.13	-0.06	-0.15	0.35	0.08	0.14	0.51	0.23	-0.06	0.48	-0.1	0.74
Cash	0.76	0.28	0.45	0.32	0.41	0.46	-0.62	-0.67	0.02		0.55	0.27	0.72	0.72	0.7	0.29	0.7	0.65	0.38	0.54	0.74	0.76	0.68	0.58	-0.74	0.0
Non Current Assets Total	0.28	0.79	0.52	0.3	-0.21	0.92	0.15	-0.76	0.12	0.55		0.3	0.25	0.77	0.65	0.63	0.47	0.6	0.55	0.92	0.24	0.62	0.81	0.17	-0.64	0.04
Non Currrent Assets Other	0.03	-0.17	-0.07	-0.18	-0.13	-0.1	-0.44	0.0	-0.17	0.27	0.3		0.03	-0.04	0.04	0.26	0.05	0.0	0.32	-0.07	0.02	0.02	0.03	-0.15	-0.19	-0.08
Cash And Short Term Investments	0.99	0.27	0.33	0.49	0.76	0.24	-0.4	-0.41	0.52	0.72	0.25	0.03		0.46	0.31	0.03	0.26	0.41	0.12	0.26	0.99	0.48	0.27	0.87	-0.42	0.58
Common Stock Total Equity	0.53	0.6	0.63	0.55	0.26	0.82	-0.11	-0.98	0.24	0.72	0.77	-0.04	0.46		0.92	0.17	0.8	0.91	0.16	0.86	0.51	0.94	0.87	0.57	-0.78	0.06
Common Stock Shares Outstanding	0.39	0.36	0.68	0.46	0.21	0.66	-0.26	-0.93	0.13	0.7	0.65	0.04	0.31	0.92		0.09	0.86	0.96	0.18	0.72	0.37	0.97	0.82	0.42	-0.73	-0.16
Non Current Liabilities Total	0.01	0.6	0.24	-0.09	-0.61	0.55	0.22	-0.16	-0.06	0.29	0.63	0.26	0.03	0.17	0.09		-0.08	-0.03	0.91	0.54	-0.01	0.0	0.43	-0.34	-0.34	-0.04
Other Current Assets	0.35	0.19	0.48	0.34	0.29	0.47	-0.42	-0.79	-0.15	0.7	0.47	0.05	0.26	0.8	0.86	-0.08		0.82	-0.02	0.54	0.34	0.87	0.73	0.44	-0.69	-0.32
Other Stockholder Equity	0.48	0.35	0.73	0.66	0.33	0.63	-0.22	-0.96	0.35	0.65	0.6	0.0	0.41	0.91	0.96	-0.03	0.82		0.1	0.66	0.46	0.97	0.7	0.53	-0.73	0.04
Total Liab	0.1	0.45	0.4	0.1	-0.5	0.44	0.06	-0.21	0.08	0.38	0.55	0.32	0.12	0.16	0.18	0.91	-0.02	0.1		0.42	0.08	0.11	0.32	-0.28	-0.37	-0.07
Property Plant And Equipment Gross	0.31	0.86	0.59	0.32	-0.13	0.99	0.25	-0.82	0.14	0.54	0.92	-0.07	0.26	0.86	0.72	0.54	0.54	0.66	0.42		0.28	0.68	0.91	0.27	-0.62	0.03
Total Current Assets	1.0	0.26	0.36	0.5	0.79	0.25	-0.43	-0.45	0.51	0.74	0.24	0.02	0.99	0.51	0.37	-0.01	0.34	0.46	0.08	0.28		0.54	0.32	0.9	-0.47	0.55
Common Stock	0.56	0.37	0.65	0.57	0.39	0.64	-0.31	-0.95	0.23	0.76	0.62	0.02	0.48	0.94	0.97	0.0	0.87	0.97	0.11	0.68	0.54		0.76	0.6	-0.76	-0.02
Other Liab	0.34	0.64	0.55	0.17	-0.01	0.84	-0.06	-0.81	-0.06	0.68	0.81	0.03	0.27	0.87	0.82	0.43	0.73	0.7	0.32	0.91	0.32	0.76		0.31	-0.69	-0.13
Net Tangible Assets	0.9	0.24	0.28	0.5	0.91	0.24	-0.3	-0.49	0.48	0.58	0.17	-0.15	0.87	0.57	0.42	-0.34	0.44	0.53	-0.28	0.27	0.9	0.6	0.31		-0.37	0.51
Other Assets	-0.47	-0.44	-0.36	-0.35	-0.13	-0.59	0.26	0.8	-0.1	-0.74	-0.64	-0.19	-0.42	-0.78	-0.73	-0.34	-0.69	-0.73	-0.37	-0.62	-0.47	-0.76	-0.69	-0.37		-0.15
Long Term Debt	0.54	0.28	0.02	0.3	0.45	0.07	0.22	-0.07	0.74	0.0	0.04	-0.08	0.58	0.06	-0.16	-0.04	-0.32	0.04	-0.07	0.03	0.55	-0.02	-0.13	0.51	-0.15

Click cells to compare fundamentals

Clearside Biomedical Account Relationship Matchups

Clearside Biomedical fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	26.8M	19.3M	42.9M	51.3M	34.0M	37.7M
Short Long Term Debt Total	6.4M	2.0M	675K	1.3M	43.0M	45.2M
Other Current Liab	2.9M	1.2M	2.9M	3.8M	3.8M	2.6M
Total Current Liabilities	10.9M	9.9M	4.6M	5.8M	6.8M	7.6M
Total Stockholder Equity	11.2M	8.8M	38.0M	10.6M	(15.9M)	(15.1M)
Property Plant And Equipment Net	1.2M	944K	607K	1.9M	3.9M	4.1M
Net Debt	(16.2M)	(15.3M)	(29.8M)	(47.0M)	14.1M	14.8M
Retained Earnings	(237.7M)	(255.9M)	(255.5M)	(288.4M)	(320.9M)	(304.9M)
Accounts Payable	1.3M	2.0M	941K	1.1M	2.2M	2.5M
Cash	22.6M	17.3M	30.4M	48.3M	28.9M	23.0M
Non Current Assets Total	1.6M	1.2M	767K	3.0M	3.9M	4.1M
Non Currrent Assets Other	360K	260K	160K	1.1M	30K	28.5K
Cash And Short Term Investments	22.6M	17.3M	30.4M	48.3M	28.9M	34.0M
Common Stock Total Equity	44K	52K	60K	61K	70.2K	73.7K
Common Stock Shares Outstanding	38.2M	46.5M	59.9M	60.2M	61.8M	37.3M
Liabilities And Stockholders Equity	26.8M	19.3M	42.9M	51.3M	34.0M	37.7M
Non Current Liabilities Total	4.7M	616K	288K	34.0M	43.1M	45.3M
Other Current Assets	1.5M	831K	1.7M	1.1M	1.0M	670.7K
Other Stockholder Equity	248.8M	264.6M	293.4M	299.0M	304.9M	184.5M
Total Liab	15.6M	10.6M	4.9M	40.7M	49.9M	27.5M
Property Plant And Equipment Gross	1.2M	944K	1.6M	2.7M	4.8M	5.0M
Total Current Assets	25.2M	18.1M	42.1M	48.3M	30.1M	35.9M
Common Stock	44K	52K	60K	61K	63K	37.2K
Other Liab	605K	10.5M	4.6M	34.0M	39.1M	41.0M
Net Tangible Assets	11.2M	8.8M	38.0M	10.6M	12.2M	15.8M
Other Assets	360K	260K	160K	30K	1.0	0.95
Short Long Term Debt	3.2M	556K	1.3M	991K	891.9K	847.3K
Short Term Debt	1.7M	1.7M	774K	698K	728K	1.2M
Property Plant Equipment	1.2M	944K	238K	755K	868.3K	643.4K
Capital Surpluse	248.8M	264.6M	293.4M	299.0M	343.8M	222.9M
Retained Earnings Total Equity	(237.7M)	(255.9M)	(255.5M)	(288.4M)	(259.6M)	(272.6M)
Net Invested Capital	16.3M	9.8M	38.0M	10.6M	(15.9M)	(15.1M)
Net Working Capital	14.3M	8.2M	37.5M	43.6M	23.3M	29.1M
Capital Stock	44K	52K	60K	61K	63K	57.2K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether Clearside Biomedical is a strong investment it is important to analyze Clearside Biomedical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Clearside Biomedical's future performance. For an informed investment choice regarding Clearside Stock, refer to the following important reports:

How To Invest In Clearside

Details

Is Clearside Stock a good investment?

Details

What is Clearside Biomedical's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearside Biomedical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For information on how to trade Clearside Stock refer to our How to Trade Clearside Stock guide.

You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clearside Biomedical. If investors know Clearside will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clearside Biomedical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.45)

Revenue Per Share

0.112

Quarterly Revenue Growth

(0.91)

Return On Assets

(0.44)

Return On Equity

(13.10)

The market value of Clearside Biomedical is measured differently than its book value, which is the value of Clearside that is recorded on the company's balance sheet. Investors also form their own opinion of Clearside Biomedical's value that differs from its market value or its book value, called intrinsic value, which is Clearside Biomedical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clearside Biomedical's market value can be influenced by many factors that don't directly affect Clearside Biomedical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Clearside Biomedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clearside Biomedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clearside Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Clearside Begin Period Cash Flow vs Ev To Free Cash Flow Analysis

Begin Period Cash Flow vs Ev To Free Cash Flow

Begin Period Cash Flow vs Ev To Free Cash Flow Correlation Analysis

Correlation Coefficient

Begin Period Cash Flow

Ev To Free Cash Flow

Clearside Biomedical fundamental ratios Correlations

Clearside Biomedical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Clearside Biomedical fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 0.99	Total Assets
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net
Total Current Assets	+ 0.99	Cash And Short Term Investments
Common Stock	+ 0.97	Common Stock Shares Outstanding
Common Stock	+ 0.97	Other Stockholder Equity

Common Stock Total Equity	- 0.98	Retained Earnings
Other Stockholder Equity	- 0.96	Retained Earnings
Common Stock	- 0.95	Retained Earnings
Common Stock Shares Outstanding	- 0.93	Retained Earnings
Property Plant And Equipment Gross	- 0.82	Retained Earnings
Other Liab	- 0.81	Retained Earnings